Quantcast
Last updated on April 24, 2014 at 1:21 EDT

InspireMD Postpones $40 Million Registered

November 16, 2012

TEL AVIV, Israel, November 16, 2012 /PRNewswire/ –

InspireMD, Inc. (“InspireMD” or the “Company”) announced that, based on recent adverse
market conditions, it has chosen to postpone its planned registered public offering of $40
million worth of its shares of common stock until a later date.

InspireMD’s registration statement on Form S-1, as filed with the Securities and
Exchange Commission, has not been withdrawn and the Company expects to continue to
evaluate the timing for the offering.

About InspireMD, Inc.

InspireMD is a medical device company focusing on the development and
commercialization of its proprietary stent system technology, MGuard(TM). InspireMD
intends to pursue applications of this technology in coronary, carotid and peripheral
artery procedures. InspireMD’s common stock is quoted on the OTC under the ticker symbol
NSPR.

About MGuard(TM) Embolic Protection Coronary Stent

MGuard(TM) EPS combines a coronary stent merged with an embolic protection
specifically designed for acute MI patients. The embolic protection is comprised of an
ultra-thin polymer micron net that is integrated with the stent. The MGuard EPS is
designed to provide outstanding and lifelong embolic protection, without affecting
deliverability. MGuard EPS is CE Mark approved. MGuard(TM) is not approved for sale in the
U.S. by the U.S. Food and Drug Administration at this time.

Forward-looking Statements:

This press release contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown risks and uncertainties,
many of which are beyond the Company’s control, and cannot be predicted or quantified and
consequently, actual results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, without limitation,
risks and uncertainties associated with (i) market acceptance of our existing and new
products, (ii) negative clinical trial results or lengthy product delays in key markets,
(iii) an inability to secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much larger, multi-national
companies, (v) product liability claims, (vi) our limited manufacturing capabilities and
reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement
by governmental and other third party payers for our products, (viii) our efforts to
successfully obtain and maintain intellectual property protection covering our products,
which may not be successful, (ix) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers
for certain product components, (xi) the fact that we will need to raise additional
capital to meet our business requirements in the future and that such capital raising may
be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in
multiple foreign jurisdictions, exposing us to foreign currency exchange rate
fluctuations, logistical and communications challenges, burdens and costs of compliance
with foreign laws and political and economic instability in each jurisdiction. More
detailed information about the Company and the risk factors that may affect the
realization of forward-looking statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s Transition Report on
From 10-K/T and its Quarterly Reports on Form 10-Q. Investors and security holders are
urged to read these documents free of charge on the SEC’s web site at
http://www.sec.gov. The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.

        For additional information:
        InspireMD Desk
        Redington, Inc.
        +1-212-926-1733
        +1-203-222-7399
        inspiremd@redingtoninc.com

SOURCE InspireMD, Inc.


Source: PR Newswire